PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB
Nasdaq · XNAS · stock · Laboratory Analytical Instruments
Chart by TradingView
3/9
Piotroski F — financial health
-13.42
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $160.0M | -$546.4M | $45.8M | -$113.9M | $5.3M |
| 2024 | $154.0M | -$309.9M | $37.3M | -$212.2M | $506.6M |
| 2023 | $200.5M | -$306.7M | $52.8M | -$268.0M | $701.3M |
| 2022 | $128.3M | -$314.2M | $49.0M | -$280.0M | $562.9M |
| 2021 | $130.5M | -$181.2M | $58.9M | -$117.1M | $791.0M |
| 2020 | $78.9M | $29.4M | $32.6M | $18.5M | $335.5M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.42 (distress)
- Working capital / assets 0.385
- Retained earnings / assets -3.438
- EBIT / assets -0.706
- Equity / liabilities 0.007
Source: SEC EDGAR filings · CIK 0001299130 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.